Is Supernus Pharmaceuticals, Inc. overvalued or undervalued?

As of 22 August 2025, the valuation grade for Supernus Pharmaceuticals, Inc. has moved from fair to expensive. The company is currently overvalued, as indicated by its P/E ratio of 29, which is significantly higher than the industry average, and an EV to EBITDA ratio of 9.02. Additionally, the PEG ratio stands at an exceptionally low 0.02, suggesting that the stock may not be priced appropriately relative to its growth prospects.
In comparison to its peers, Supernus Pharmaceuticals has a P/E ratio of 37.12, which is notably higher than Harmony Biosciences Holdings, Inc. at 11.40 and Amphastar Pharmaceuticals, Inc. at 11.49, both of which are considered attractive. Furthermore, while Supernus has shown strong returns over the past year at 44.88%, this is overshadowed by the S&P 500's return of 17.14% in the same period, indicating that despite recent performance, the stock's valuation may not be justified.